Search results
Results From The WOW.Com Content Network
Chemotherapy-induced peripheral neuropathy (CIPN) is a nerve-damaging side effect of antineoplastic agents in the common cancer treatment, chemotherapy. [1] CIPN afflicts between 30% and 40% of patients undergoing chemotherapy.
The systems of the body most affected by chemotherapy drugs include visual and semantic memory, attention and motor coordination and executive functioning. [9] [10] These effects can impair a chemotherapy patient's ability to understand and make decisions regarding treatment, perform in school or employment and can reduce quality of life. [10]
Peripheral neuropathy may be classified according to the number and distribution of nerves affected (mononeuropathy, mononeuritis multiplex, or polyneuropathy), the type of nerve fiber predominantly affected (motor, sensory, autonomic), or the process affecting the nerves; e.g., inflammation (), compression (compression neuropathy), chemotherapy (chemotherapy-induced peripheral neuropathy).
radiotherapy, which can cause skin reactions, enteritis, fibrosis, myelopathy, bone necrosis, neuropathy or plexopathy; chemotherapy, often associated with chemotherapy induced peripheral neuropathy, mucositis, joint pain, muscle pain, and abdominal pain due to diarrhea or constipation; hormone therapy, which sometimes causes pain flares;
With increasing cancer treatment survival rates, the quality of life for its survivors has become a public health priority. [1] The effects of RILP can be debilitating. With no effective treatment to control radiation damage's progressive nature, limb dysfunction is the likely result. [10] Radiation damage's outcome is related to its initial ...
Hand-foot invariably recurs with the resumption of chemotherapy. Long-term chemotherapy may also result in reversible palmoplantar keratoderma. Symptoms resolve 1–2 weeks after cessation of chemotherapy. [6] The range is 1–5 weeks, so it has recovered by the time the next cycle is due.
Another study by Jianren Mao et al. examined how “intrathecal treatment with dextrorphan or ketamine potently reduces pain-related behaviours in a rat model of peripheral mononeuropathy”. [11] Mao understands that “the experimental neuropathic pain syndrome seen in CCI rats is similar in many respects to the neuropathic pain syndrome seen ...
[49] [50] This latter condition was later termed multifocal motor neuropathy [51] This distinction is important because multifocal motor neuropathy responds to intravenous immunoglobulin alone, while chronic inflammatory demyelinating polyneuropathy responds to intravenous immunoglobulin, steroids and plasma exchange. [52]